Ozempic and Wegovy (and Rybelsus, which is oral semaglutide) are GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists, commonly referred to as GLP-1s) and are the only FDA-approved drugs that contain the active ingredient semaglutide
We prioritize your health and well-being and will work to ensure the treatment is as effective and comfortable as possible
This contributes to greater suppression of appetite and improved blood glucose levels
Its common for patients to feel slightly underwhelmed during this initial phasebut its a critical foundation to reduce side effects later during dose increases
Unlike GLP-1 agonists, DPP-4 inhibitors do not affect satiety, gastric emptying, or induce weight loss
If you have a history of specific allergies to sulfur or the amino acids involved, you should proceed with caution